Syndax Pharmaceuticals, Inc. Operating Lease Right-of-Use Assets
Syndax Pharmaceuticals, Inc. (SNDX) had Operating Lease Right-of-Use Assets of $1.08 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-04
- 2026-06-30: Operating Lease, Right-of-Use Asset $1.08M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $1.21M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.34M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $1.47M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $1.08M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $1.21M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $1.34M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $1.47M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $1.63M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $1.80M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $2.02M 10-K · filed 2026-02-26 |
| 2024-10-31 | $1.50M 10-K · filed 2026-02-26 |
| 2024-09-30 | $756.00K 10-Q · filed 2024-11-05 |
| 2024-06-30 | $1.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.24M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.49M 10-K · filed 2025-03-03 |
| 2023-09-30 | $1.73M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.97M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $929.00K 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.04M 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.15M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $774.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $873.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $983.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $1.09M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $338.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $434.00K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $290.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $396.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $502.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $608.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $716.00K 10-K · filed 2021-03-12 |
| 2019-09-30 | $826.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $1.09M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $1.21M 10-Q · filed 2019-05-08 |
| 2019-01-01 | $1.30M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |